Market Research Report
Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs
|Published by||GlobalData||Product code||576589|
|Published||Content info||71 Pages
Delivery time: 1-2 business days
|Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs|
|Published: October 1, 2017||Content info: 71 Pages||
Ophthalmology is a therapy area that encompasses the diagnosis, treatment and prevention of diseases associated with the eyes and the visual system. The visual system, including the eye and its surrounding structures, can be affected by a number of pathological conditions. In 2015, it was estimated that over 3 million Americans suffer from visual impairment, defined as having 20/40 vision or worse after best possible correction. A person with 20/40 vision is able to read letters from 20 feet away that an individual with ''normal'' 20/20 vision could read from 40 feet, so a person that can still not perform this after best possible intervention with glasses or contact lenses is classed as being visually impaired.
Ophthalmology pipeline has a highly active deals landscape. There were 271 licensing deals and 152 co-development deals completed between 2006 and 2016 across the therapy area, of which 94 licensing deals and 33 co-development deals had a disclosed value. Many products in the ophthalmology pipeline have previously been involved in licensing and co-development deals. Most of these are in the Preclinical stage of development, although many deals also took place for products at Phase II.
The pipeline contains a diverse range of molecular targets, and no single target dominates by any clear margin. However, products acting on components of the immune system - largely cytokines and cytokine receptors - and its regulatory signaling pathways make up the largest segment, followed by angiogenesis inhibitors. Generally, the composition by molecular target across the pipeline suggests that product development is shifting away from the type of therapies that currently dominate the market, indicating that the available therapeutic options could diversify.
The report "Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs" assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products. In-depth analysis reveals that the level of innovation within the therapy area pipeline is high, with strong potential for drugs to address unmet needs and be commercially lucrative.